A case of a hemodialysis patient with secondary hyperparathyroidism who was resistant to etelcalcetide treatment but not to cinacalcet hydrochloride
| Autor: | Yasushi Makino, Mariko Anayama, Masaki Nagasawa, Masanori Tokumoto, Katsuhiko Tamura, Shigekazu Kurihara, Hironori Nakamura |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Etelcalcetide
medicine.medical_specialty Cinacalcet Calcitriol business.industry medicine.medical_treatment Urology Parathyroid hormone General Medicine medicine.disease medicine.anatomical_structure Parathyroid Hormone Renal Dialysis Cinacalcet Hydrochloride medicine Humans Calcium Hyperparathyroidism Secondary Secondary hyperparathyroidism Parathyroid gland Hemodialysis Peptides business medicine.drug |
| Zdroj: | CEN Case Reports. 11:254-258 |
| ISSN: | 2192-4449 |
| DOI: | 10.1007/s13730-021-00664-0 |
| Popis: | Although both cinacalcet and etelcalcetide are calcimimetics that directly inhibit parathyroid hormone (PTH) secretion by activating the calcium (Ca)-sensing receptor (CaSR), their binding sites are different. We report a first case of a hemodialysis (HD) patient with secondary hyperparathyroidism (SHPT), in whom cinacalcet, but not etelcalcetide, could reduce serum intact PTH (i-PTH) levels. A HD patient received total parathyroidectomy (PTx) with auto-transplantation 16 years earlier. Due to SHPT relapse, cinacalcet was started at 7 years after PTx. His i-PTH levels had been controlled with both 75–100 mg of cinacalcet and 4.5 μg/week of calcitriol for a year before switching from cinacalcet to etelcalcetide. At 1 month following the switch, his serum i-PTH level increased to 716 pg/mL. The dose of etelcalcetide was gradually increased and finally reached the maximal dose of 45 mg/week. Because even the maximal dose of etelcalcetide for > 4 months did not reduce his serum i-PTH levels to |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink